Michael P Blair to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications Michael P Blair has written about Vascular Endothelial Growth Factor A.
Connection Strength
0.716
-
Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol. 2010 Aug; 128(8):1080-1.
Score: 0.325
-
Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844). Ophthalmology. 2017 10; 124(10):e74-e75.
Score: 0.134
-
Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar; 47(3):280-3.
Score: 0.120
-
Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. Ophthalmic Surg Lasers Imaging Retina. 2020 09 01; 51(9):486-493.
Score: 0.041
-
Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis. Retin Cases Brief Rep. 2014; 8(1):24-9.
Score: 0.026
-
Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013 Jun; 17(3):323-5.
Score: 0.025
-
Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012 Aug; 130(8):1000-6.
Score: 0.023
-
Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012 Jun; 130(6):801-2.
Score: 0.023